Sinorda and Porton Partner to Advance Cell and Gene Therapy Products
publication date: Apr 25, 2022
Guizhou Sinorda Biomedicine, a novel cell and gene therapy company, announced a long-term strategic cell and gene therapy R&D partnership with CDMO Suzhou Porton Advanced Solutions. Sinorda is developing innovative digestive tract, immunotherapy and oncolytic virus products, with several candidates in clinical stage. Porton will provide services to accelerate the development of Sinorda’s cell therapies, including its Sentinel lymph node T cell immunotherapy for colorectal cancer. Porton offers an end-to-end gene and cell therapy CDMO service platform for plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy and Bacterial Therapy. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.